Healthpeak Q1 AFFO beats, raises guidance after senior housing IPO and Blackstone recap

What happened

Healthpeak Properties reported Q1 2026 AFFO of $0.45 per share and raised full-year guidance, following the IPO of its senior housing business, a joint venture recapitalization with Blackstone, and a $100 million stock buyback. These moves demonstrate management's commitment to unlocking value and strengthening the balance sheet, but the underlying business remains mixed: outpatient and CCRC segments perform well, while the lab portfolio continues to face headwinds from oversupply and weak biopharma funding. The senior housing IPO and Blackstone JV effectively monetize assets at attractive valuations, reducing exposure to a volatile sector and providing capital to reinvest or reduce debt. However, the stock buyback, while signaling confidence, uses capital that could otherwise fund growth or de-lever, and the raised guidance likely still assumes lab occupancy stabilizes rather than recovers quickly. Overall, the quarter reinforces the thesis that Healthpeak's core outpatient and CCRC assets provide a stable cash flow base, but the lab segment and higher interest expenses keep a lid on FFO growth and valuation multiples.

Implication

In the near term, the senior housing IPO and Blackstone recap reduce portfolio complexity and provide capital, supporting the dividend and balance sheet. The raised guidance suggests management is confident in outpatient/CCRC trends and merger synergies, but the lab segment's occupancy and NOI trajectory remain key variables. The $100 million buyback is modest relative to market cap and indicates management sees value at these levels, but it does not address the structural lab issues. Investors should monitor lab leasing and occupancy metrics in upcoming quarters; a stabilization would confirm the bull case, while further deterioration would push the stock toward the bear case. Overall, the risk/reward is balanced, with a base-case value around $18, but upside depends on lab improvement.

Thesis delta

The Q1 2026 results and capital actions modestly improve the near-term outlook by providing balance sheet flexibility and signaling management's commitment to shareholder value, but they do not alter the fundamental thesis that lab oversupply and rising interest costs cap valuation. The thesis remains a potential buy with a base case of $18, assuming outpatient/CCRC strength continues to offset lab weakness. The increased guidance supports the low-to-mid single-digit FFO growth narrative but does not justify a premium multiple until lab trends improve.